Shopping Cart
- Remove All
- Your shopping cart is currently empty
Compound (S)-7, also known as PPARα/γ agonist 4, is a dual potent agonist for PPARα and PPARγ with EC50 values of 0.061 μM and 1.42 μM, respectively. This compound exhibits oral efficacy and operates through an insulin-independent mechanism, featuring mitochondrial pyruvate carrier inhibition and antidiabetic properties. PPARα/γ agonist 4 holds potential for research in dyslipidemic type 2 diabetes.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | Compound (S)-7, also known as PPARα/γ agonist 4, is a dual potent agonist for PPARα and PPARγ with EC50 values of 0.061 μM and 1.42 μM, respectively. This compound exhibits oral efficacy and operates through an insulin-independent mechanism, featuring mitochondrial pyruvate carrier inhibition and antidiabetic properties. PPARα/γ agonist 4 holds potential for research in dyslipidemic type 2 diabetes. |
In vitro | PPARα/γ agonist 4 (100 nM, 24 hours) enhances glucose uptake and metabolism in the C2C12 cell line and prevents lipid accumulation in liver or muscle cells by boosting mitochondrial activity associated with fatty acid degradation. |
In vivo | Compound PPARα/γ agonist 4, administered orally at doses of 25 mg/kg and 50 mg/kg over a 15-day treatment period, exhibits dose-dependent antihyperglycemic effects and significant lipid-lowering properties in a diabetic mouse model. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.